News | Magnetic Resonance Imaging (MRI) | July 12, 2016

ACR Manual on Contrast Media Addresses FDA Gadolinium Safety Concerns

Updated resource for radiologists guides safe, effective use of contrast media in daily practice

gadolinium, ACR Manual on Contrast Media, update, FDA safety concerns

July 12, 2016 — The updated American College of Radiology (ACR) Manual on Contrast Media contains a statement addressing the U.S. Food and Drug Administration (FDA) safety communication on use of gadolinium-based contrast agents for magnetic resonance imaging (MRI).

Gadolinium-based contrast agents are administered to approximately 30 million patients every year to improve the diagnostic accuracy of MR examinations. Researchers have found that gadolinium-based contrast agents may leave deposits in the brain, bone and other organs. “If the decision is made to use a gadolinium-based contrast agent for an MRI study for an individual patient, multiple factors need to be considered … including diagnostic efficacy, relaxivity, rate of adverse reactions, dosing/concentration and propensity to deposit in more sensitive organs, such as the brain,” notes a joint statement from the ACR and the American Society of Neuroradiology (ASNR).

“This vital guide for radiologists enhances the safe and effective use of contrast media in daily practice to ensure optimal patient care,” said Jacqueline Bello, M.D., FACR, chair of the ACR Commission on Quality and Safety. “The timely inclusion of the ACR and ASNR joint statement addresses questions posed by many radiology professionals about gadolinium-based contrast agents in the previous months,” she added.

“Reviews from radiologists show that this reference on contrast media is a practical and valuable resource in support of the millions of radiological examinations that may be assisted by intravascular contrast media annually,” said James H. Ellis, M.D., FACR, chair of the ACR Committee on Drugs and Contrast Media. He noted that the manual continues to be available for free as a frequently updated downloadable document on the ACR website.

Version 10.2 of the resource for using contrast media in diagnostic imaging includes:

  • An updated footnote in “Metformin,” concerning the FDA’s April 2016 guidance on patients who take this medication and who receive iodinated contrast media;
  • Information and new references about intra-osseous injection in “Injection of Contrast Media”; and
  • The addition of a document version history, so users may track changes from version to version.

For more information: www.acr.org


Related Content

News | Magnetic Resonance Imaging (MRI)

March 26, 2026 —The heart’s ability to use oxygen efficiently is a critical indicator of its health, but tests to ...

Home March 30, 2026
Home
News | Magnetic Resonance Imaging (MRI)

March 25, 2026 A Penn Medicine–led team has developed a first‑of‑its‑kind artificial intelligence system that interprets ...

Home March 27, 2026
Home
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Polarean, a commercial-stage medical imaging company advancing functional MRI of the lungs, has expanded ...

Home January 21, 2026
Home
News | Magnetic Resonance Imaging (MRI) | Children's Hospital Los Angeles

Oct. 28, 2025 — Bronchopulmonary dysplasia (BPD) is the most common — and most serious — complication of extreme ...

Home October 31, 2025
Home
News | Magnetic Resonance Imaging (MRI)

May 12, 2025 — GE HealthCare recently unveiled Signa Sprint, an FDA 510(k) pending[1] ultra-premium wide bore 1.5T high ...

Home May 12, 2025
Home
News | Magnetic Resonance Imaging (MRI)

Nov. 21, 2024 — Royal Philips plans to unveil its next-generation 1.5T BlueSeal MR wide-bore scanner at RSNA 2024 in ...

Home November 21, 2024
Home
News | Magnetic Resonance Imaging (MRI)

February 21, 2024 — Hyperfine, Inc., a groundbreaking health technology company that has redefined brain imaging with ...

Home February 21, 2024
Home
News | Magnetic Resonance Imaging (MRI)

November 17, 2023 — Researchers from the University of Minnesota Medical School examining the cause of cardiomyopathy ...

Home November 17, 2023
Home
News | Magnetic Resonance Imaging (MRI)

June 28, 2023 — Liver disease, the UK’s third leading cause of premature death, poses a significantly greater threat to ...

Home June 28, 2023
Home
News | Magnetic Resonance Imaging (MRI)

June 20, 2023 — The US Food and Drug Administration has approved the use of iTFlow in blood flow analysis. The FDA ...

Home June 20, 2023
Home
Subscribe Now